• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Combination therapies for advanced hepatocellular carcinoma: a beacon of light or a castle in the air.

作者信息

Rai Vikrant, Mukherjee Sandeep

机构信息

Department of Translational Research, Western University of Health Sciences, Pomona, CA, USA.

Department of Medicine, Creighton University School of Medicine, Omaha, NE, USA.

出版信息

Hepatobiliary Surg Nutr. 2022 Aug;11(4):629-631. doi: 10.21037/hbsn-2022-12.

DOI:10.21037/hbsn-2022-12
PMID:36016739
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9396096/
Abstract
摘要

相似文献

1
Combination therapies for advanced hepatocellular carcinoma: a beacon of light or a castle in the air.晚期肝细胞癌的联合治疗：希望之光还是空中楼阁。
Hepatobiliary Surg Nutr. 2022 Aug;11(4):629-631. doi: 10.21037/hbsn-2022-12.
2
Carcinoma Showing Thymus-Like Differentiation (CASTLE): Cytopathological Features and Differential Diagnosis.具有胸腺样分化的癌（CASTLE）：细胞病理学特征与鉴别诊断
Acta Cytol. 2016;60(5):421-428. doi: 10.1159/000448836. Epub 2016 Sep 17.
3
[A Case of Carcinoma Showing Thymus-Like Differentiation (CASTLE) of the Thyroid].[1例甲状腺呈现胸腺样分化的癌（CASTLE）]
J UOEH. 2018;40(3):259-266. doi: 10.7888/juoeh.40.259.
4
Carcinoma showing thymus-like differentiation of the thyroid (CASTLE): a comparative study: evidence of thymic differentiation and solid cell nest origin.甲状腺呈胸腺样分化的癌（CASTLE）：一项比较研究：胸腺分化及实性细胞巢起源的证据
Am J Surg Pathol. 2006 Aug;30(8):994-1001. doi: 10.1097/00000478-200608000-00010.
5
Intrathyroidal epithelial thymoma/carcinoma showing thymus-like differentiation; comparison with thymic lymphoepithelioma-like carcinoma and a possibility of development from a multipotential stem cell.甲状腺内上皮性胸腺瘤/癌，显示胸腺样分化；与胸内淋巴上皮癌样癌的比较及可能来源于多潜能干细胞。
APMIS. 2013 Jun;121(6):523-30. doi: 10.1111/apm.12017. Epub 2012 Nov 23.
6
Histopathological study of carcinoma showing thymus-like differentiation (CASTLE).癌伴有胸腺样分化（CASTLE）的组织病理学研究。
Malays J Pathol. 2020 Aug;42(2):259-265.
7
A carcinoma showing thymus-like elements of the thyroid arising in close association with solid cell nests: evidence for a precursor lesion?甲状腺癌伴胸腺样上皮成分：与实性细胞巢密切相关的癌，是否为一种癌前病变？
Thyroid. 2013 Apr;23(4):511-6. doi: 10.1089/thy.2011.0415. Epub 2013 Mar 18.
8
Carcinoma showing thymus-like element (CASTLE) of thyroid: combined modality treatment in 3 patients with locally advanced disease.
Eur J Surg Oncol. 2007 Feb;33(1):83-5. doi: 10.1016/j.ejso.2006.09.016. Epub 2006 Nov 3.
9
The 'CASTLE' tumour: An extremely rare presentation of a thyroid malignancy. A case report.“CASTLE”肿瘤：一种极其罕见的甲状腺恶性肿瘤表现。病例报告。
Ann Med Surg (Lond). 2019 Jun 30;44:57-61. doi: 10.1016/j.amsu.2019.06.013. eCollection 2019 Aug.
10
Recurrence of carcinoma showing thymus-like differentiation (CASTLE) involving the thyroid gland.表现为胸腺样分化的癌（CASTLE）累及甲状腺的复发。
Thyroid Res. 2021 Aug 16;14(1):20. doi: 10.1186/s13044-021-00111-3.

引用本文的文献

1
Modern therapeutic approaches for hepatic tumors: progress, limitations, and future directions.肝脏肿瘤的现代治疗方法：进展、局限性及未来方向。
Discov Oncol. 2025 May 30;16(1):959. doi: 10.1007/s12672-025-02773-z.

本文引用的文献

1
Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis.索拉非尼与经动脉化疗栓塞术联合应用于肝细胞癌患者的最佳时机：一项荟萃分析。
Transl Oncol. 2021 Dec;14(12):101238. doi: 10.1016/j.tranon.2021.101238. Epub 2021 Oct 7.
2
Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy.阿替利珠单抗联合贝伐单抗治疗失败后肝细胞癌的序贯治疗
Liver Cancer. 2021 Apr;10(2):85-93. doi: 10.1159/000514312. Epub 2021 Feb 15.
3
Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development.
局部区域联合全身治疗晚期肝细胞癌：快速发展的必然趋势
Front Mol Biosci. 2021 Apr 13;8:635243. doi: 10.3389/fmolb.2021.635243. eCollection 2021.
4
Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?晚期肝细胞癌的联合治疗：我们是否看到了隧道尽头的曙光？
Hepatobiliary Surg Nutr. 2021 Apr;10(2):180-192. doi: 10.21037/hbsn-2021-7.
5
Sequencing Treatments in Hepatocellular Carcinoma: Will Value Frameworks Provide a Solution?肝细胞癌的序贯治疗：价值框架能提供解决方案吗？
JCO Oncol Pract. 2021 Apr;17(4):164-166. doi: 10.1200/OP.20.01018. Epub 2021 Feb 17.
6
Application of ASCO Value Framework to Treatment Advances in Hepatocellular Carcinoma.ASCO 价值框架在肝细胞癌治疗进展中的应用。
JCO Oncol Pract. 2021 Apr;17(4):e461-e468. doi: 10.1200/OP.20.00558. Epub 2021 Jan 7.
7
Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis.系统治疗与晚期肝细胞癌的序贯治疗选择：系统评价和网络荟萃分析。
JAMA Oncol. 2020 Dec 1;6(12):e204930. doi: 10.1001/jamaoncol.2020.4930. Epub 2020 Dec 10.
8
Transarterial chemoembolization, ablation, tyrosine kinase inhibitors, and immunotherapy (TATI): A novel treatment for patients with advanced hepatocellular carcinoma.经动脉化疗栓塞、消融、酪氨酸激酶抑制剂和免疫疗法（TATI）：晚期肝细胞癌患者的一种新治疗方法。
J Cancer Res Ther. 2020;16(2):327-334. doi: 10.4103/jcrt.JCRT_101_20.
9
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.免疫检查点抑制剂联合治疗肝细胞癌的挑战。
J Hepatol. 2020 Feb;72(2):307-319. doi: 10.1016/j.jhep.2019.09.025.
10
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.更新美国临床肿瘤学会价值框架：针对收到的评论进行的修订与思考
J Clin Oncol. 2016 Aug 20;34(24):2925-34. doi: 10.1200/JCO.2016.68.2518. Epub 2016 May 31.